These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. What have we learnt from the rosiglitazone saga? Montori VM; Shah ND BMJ; 2011 Mar; 342():d1354. PubMed ID: 21415102 [No Abstract] [Full Text] [Related]
3. Rosiglitazone saga. Should we throw the baby out with the bathwater? McDonald C BMJ; 2011 Apr; 342():d2566. PubMed ID: 21511790 [No Abstract] [Full Text] [Related]
4. Rosiglitazone and cardiovascular disease revisited. Davis TM; Prins JB Med J Aust; 2010 Aug; 193(3):134-5. PubMed ID: 20678037 [No Abstract] [Full Text] [Related]
5. The perfect storm--drug safety and rosiglitazone. Hellman R Endocr Pract; 2007; 13(3):217-8. PubMed ID: 17599850 [No Abstract] [Full Text] [Related]
8. Diabetes: making sense of the rosiglitazone controversy. Farkouh ME; Fuster V Nat Rev Cardiol; 2010 Jul; 7(7):366-7. PubMed ID: 20577297 [TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone: a thunderstorm from scarce and fragile data. Mulrow CD; Cornell J; Localio AR Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398 [No Abstract] [Full Text] [Related]
10. Rosiglitazone and cardiovascular risk. Mannucci E; Monami M; Marchionni N N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136 [No Abstract] [Full Text] [Related]
11. Rosiglitazone and the FDA. Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586 [No Abstract] [Full Text] [Related]
12. European drug regulators publish their evaluation of rosiglitazone. Mayor S BMJ; 2010 Dec; 341():c7278. PubMed ID: 21169326 [No Abstract] [Full Text] [Related]
13. Response to "Rosiglitazone no longer recommended". Strahlman E Lancet; 2009 Feb; 373(9663):544. PubMed ID: 19217986 [No Abstract] [Full Text] [Related]
17. GSK is accused of trying to suppress editorial on rosiglitazone. Tanne JH BMJ; 2010 May; 340():c2654. PubMed ID: 20484354 [No Abstract] [Full Text] [Related]
18. Rosiglitazone and cardiotoxicity--weighing the evidence. Nathan DM N Engl J Med; 2007 Jul; 357(1):64-6. PubMed ID: 17551161 [No Abstract] [Full Text] [Related]
19. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart. Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888 [No Abstract] [Full Text] [Related]
20. Rosiglitazone and cardiovascular risk. Diamond GA; Kaul S N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135 [No Abstract] [Full Text] [Related] [Next] [New Search]